ICOS is an inclusion criterion in 2 clinical trials for angioimmunoblastic T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ICOS status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 2 are phase 3 (2 open) [4].

ICOS is an inclusion criterion in 2 clinical trials for follicular T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ICOS status and follicular T-cell lymphoma as inclusion criteria, 2 are phase 3 (2 open) [4].

ICOS is an inclusion criterion in 1 clinical trial for nodal peripheral T-cell lymphoma with TFH phenotype, of which 1 is open and 0 are closed. Of the trial that contains ICOS status and nodal peripheral T-cell lymphoma with TFH phenotype as inclusion criteria, 1 is phase 3 (1 open) [4].

ICOS is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ICOS status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 3 (1 open) [4].